ClinicalTrials.gg
RecruitingNCT07854704Updated Oct 2, 2026

Goal-Directed Temperature Management During Prolonged Abdominal Surgery

An interventional study of Forced-air warming and Intravenous fluid warming in Hypothermia Following Anesthesia, Intraoperative Complications and Body Temperature Changes, sponsored by The Leningrad Regional Clinical Hospital. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by The Leningrad Regional Clinical Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Nov 2024, registered Sep 2026).
  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

During long operations on the abdomen, patients often get cold. Doctors call this perioperative hypothermia. Even a small drop in body temperature can cause problems, such as more bleeding, wound infection, and a longer stay in hospital.

To keep patients warm during surgery, doctors usually blow warm air over the body through a special blanket. However, the fluids that patients receive through a vein during surgery are normally at room temperature. These cool fluids may lower the body temperature from the inside.

This study compares two ways of keeping patients warm during operations on the abdomen that last three hours or longer.

Everyone taking part receives warm air blown over the body. In addition, one group receives fluids into a vein at room temperature, about 23 °C, which is the usual practice. The other group receives the same fluids warmed to 39 °C by a special device just before the fluid enters the vein.

Participants are placed into one of the two groups by chance, like flipping a coin. Because of the nature of the treatment, the doctors caring for the patient know which group the patient is in.

The researchers measure body temperature before, during, and at the end of surgery. They also record blood pressure, the medicines used to support blood pressure, the amount of fluid given, the amount of urine produced, and blood tests taken on the day after surgery.

This is a pilot study. Its main purpose is to find out whether a larger study would be possible. The researchers want to learn how many patients can be enrolled, whether the treatment can be given exactly as planned, and how complete the collected information is. The results will be used to plan a larger study.

Read the detailed description

Design and setting.

Single-centre, randomised, parallel-group, open-label pilot trial conducted at a regional clinical hospital in Saint Petersburg, Russian Federation. Participants are allocated in a 1:1 ratio to a control group or a study group.

Anaesthesia and warming protocol.

All participants receive general anaesthesia according to a standardised institutional protocol, and ambient operating room temperature is kept constant. In both groups, forced-air warming is applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery. In the control group, balanced crystalloid solutions are stored at 23 °C and infused without additional warming. In the study group, the same solutions are actively warmed to a target temperature of 39 °C using a medical fluid warmer positioned as close as possible to the venous access site.

Measurements.

Axillary and oesophageal temperature are recorded before induction of anaesthesia, hourly during surgery, and at transfer to the intensive care unit. Haemodynamic variables, the use and infusion rate of norepinephrine, intraoperative crystalloid volume and urine output are recorded throughout surgery. Stroke volume, cardiac output and extracellular fluid volume are assessed by tetrapolar impedance rheography. Base excess, plasma lactate, C-reactive protein and the SOFA score are recorded on the first postoperative day.

Randomisation and allocation concealment.

The allocation sequence is generated using random number tables. Allocation is concealed by sequentially numbered, sealed, opaque envelopes, opened after eligibility is confirmed and written informed consent is obtained. Blinding of the anaesthesia team is not feasible because of the nature of the intervention.

Withdrawal criteria.

Participants are withdrawn from analysis in case of withdrawal of informed consent, errors in data recording, or intraoperative change in the extent of the planned surgical procedure.

Feasibility assessment.

In addition to the clinical outcome measures, the following feasibility parameters are recorded: the proportion of screened patients who are eligible and randomised, the proportion of eligible patients who consent, adherence to the allocated intervention, the proportion of randomised participants with analysable data, and completeness of data for the primary outcome measure. These parameters will be used to determine whether a definitive multicentre trial is feasible and to inform its sample size.

02

Conditions studied

  • Hypothermia Following Anesthesia
  • Intraoperative Complications
  • Body Temperature Changes
  • Anesthesia, General

Keywords

  • perioperative hypothermia
  • inadvertent perioperative hypothermia
  • goal-directed temperature management
  • intravenous fluid warming
  • forced-air warming
  • normothermia
  • abdominal surgery
  • pilot study
  • feasibility study
03

In context

Intraoperative Complications

92 studies on the registry are indexed under Intraoperative Complications; 19 are open to participants now.

This study's planned enrollment of 61 is close to the median of 67 across 48 interventional studies indexed under Intraoperative Complications.

Browse Intraoperative Complications studies →

Lead sponsor

The Leningrad Regional Clinical Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Age 18 years or older
  • Scheduled abdominal surgery with an expected duration of at least 3 hours

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • End-stage chronic somatic disease
  • Axillary temperature above 37.0 °C before surgery
  • Documented thermoregulatory disorder of any origin, including disorders due to ongoing infectious or disease or traumatic brain injury
  • Chronic heart failure stage 2 according to the classification of the Russian Society of Cardiology
  • Active infection before surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (estimated)

Study arms

  • Active comparator
    Control group

    Forced-air warming applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery, combined with intravenous infusion of balanced crystalloid solutions stored at 23 °C and administered without additional warming.

    Device: Forced-air warming · Other: Unwarmed intravenous fluids

  • Experimental
    Study group

    Forced-air warming applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery, combined with intravenous infusion of the same balanced crystalloid solutions actively warmed to a target temperature of 39 °C by a medical fluid warmer positioned as close as possible to the venous access site.

    Device: Forced-air warming · Device: Intravenous fluid warming

Interventions

  • DeviceForced-air warming

    Forced-air warming system with an upper body blanket; airflow temperature set at 37 °C; applied identically in both groups from induction of anaesthesia until the end of surgery.

    Also known as: WarmTouch WT-5900

  • DeviceIntravenous fluid warming

    Balanced crystalloid solutions actively warmed to a target temperature of 39 °C using a medical fluid warmer; the infusion line is placed inside the heating element as close as possible to the venous access site.

    Also known as: IRIS medical fluid warmer

  • OtherUnwarmed intravenous fluids

    Balanced crystalloid solutions stored at an ambient temperature of 23 °C and administered intravenously without additional warming.

06

What researchers measure

Primary outcomes

  1. Core body temperature at admission to the intensive care unit

    Oesophageal temperature measured at the time of transfer of the participant from the operating room to the intensive care unit, in degrees Celsius.

    Time frame: At transfer to the intensive care unit, up to 12 hours after skin incision

Secondary outcomes

  1. Perioperative axillary temperature

    Axillary temperature measured with a contact thermometer. Measured in degrees Celsius.

    Time frame: Before induction of anaesthesia, hourly during surgery, and at admission to the intensive care unit, up to 12 hours

  2. Perioperative oesophageal temperature

    Core temperature measured with an oesophageal probe. Measured in degrees Celsius.

    Time frame: Hourly from 1 hour after start of surgery until admission to the intensive care unit, up to 12 hours

  3. Proportion of participants requiring norepinephrine infusion

    Number of participants who received an intraoperative norepinephrine infusion, divided by the number of participants analysed in the group, expressed as a percentage.

    Time frame: Intraoperative period, up to 12 hours

  4. Time from skin incision to initiation of norepinephrine infusion

    Interval between skin incision and the start of norepinephrine infusion, assessed only in participants who received norepinephrine. Measured in minutes.

    Time frame: Intraoperative period, up to 12 hours

  5. Norepinephrine infusion rate

    Rate of intraoperative norepinephrine infusion, assessed only in participants who received norepinephrine. Measured in micrograms per kilogram per minute.

    Time frame: Intraoperative period, up to 12 hours

  6. Volume of intraoperative crystalloid infusion

    Total volume of balanced crystalloid solutions administered intravenously during surgery. Measured in millilitres.

    Time frame: From skin incision to end of surgery, up to 12 hours

  7. Intraoperative urine output

    Total volume of urine collected during surgery. Measured in millilitres.

    Time frame: From skin incision to end of surgery, up to 12 hours

  8. Stroke volume measured by tetrapolar impedance rheography

    Stroke volume assessed non-invasively by tetrapolar impedance rheography. Measured in millilitres.

    Time frame: From before induction of anaesthesia, hourly during surgery, up to 12 hours

  9. Cardiac output measured by tetrapolar impedance rheography

    Cardiac output assessed non-invasively by tetrapolar impedance rheography. Measured in litres per minute.

    Time frame: From before induction of anaesthesia, hourly during surgery, up to 12 hours

  10. Change in extracellular fluid volume measured by tetrapolar impedance rheography

    Relative change in extracellular fluid volume assessed by tetrapolar impedance rheography. Expressed as a percentage.

    Time frame: From start of surgery to end of surgery, up to 12 hours

  11. Base excess in venous blood

    Base excess determined by venous blood gas analysis. Measured in millimoles per litre.

    Time frame: Postoperative day 1

  12. Plasma lactate concentration

    Lactate concentration determined in venous blood. Measured in millimoles per litre.

    Time frame: Postoperative day 1

  13. Serum C-reactive protein concentration

    C-reactive protein concentration determined in venous blood. Measured in milligrams per litre.

    Time frame: Postoperative day 1

  14. Total SOFA score

    Sequential Organ Failure Assessment score, calculated as the sum of six organ system subscores. Total score ranges from 0 to 24, with higher scores indicating greater organ dysfunction.

    Time frame: Postoperative day 1

Other outcomes

  1. Proportion of screened participants who were randomised

    Feasibility outcome. Number of randomised participants divided by the number of patients screened for eligibility, expressed as a percentage.

    Time frame: From start of enrolment through study completion, up to 32 months

  2. Proportion of eligible participants who provided informed consent

    Feasibility outcome. Number of participants who provided written informed consent divided by the number of patients who met the eligibility criteria, expressed as a percentage.

    Time frame: From start of enrolment through study completion, up to 32 months

  3. Recruitment rate

    Feasibility outcome. Number of randomised participants per month of enrolment.

    Time frame: From start of enrolment through study completion, up to 32 months

  4. Adherence to the allocated intervention

    Feasibility outcome. Number of randomised participants who received the allocated intervention in full, divided by the number of randomised participants, expressed as a percentage.

    Time frame: From start of enrolment through study completion, up to 32 months

  5. Proportion of randomised participants with analysable data

    Feasibility outcome. Number of randomised participants whose data were available for analysis of the clinical outcome measures, divided by the number of randomised participants, expressed as a percentage.

    Time frame: From start of enrolment through study completion, up to 32 months

  6. Completeness of data for the primary outcome measure

    Feasibility outcome. Number of analysed participants with a recorded value of the primary outcome measure, divided by the number of analysed participants, expressed as a percentage.

    Time frame: From start of enrolment through study completion, up to 32 months

07

Study locations

1 of 1 sites recruiting
  • The Leningrad Regional Clinical Hospital
    Saint Petersburg, 194291, Russia
    Recruiting
    • Valentin S Kozlov, MD · Contactkozlov.vs@47lokb.ru · +7-931-250-79-30
    • Alexey S Rumyantsev-Aleksandrov, MD · Sub investigator
    • Valentin S Kozlov, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the corresponding author, following approval of a methodologically sound proposal.

Time frame: Beginning 6 months after publication of the main results and ending 3 years thereafter.

Access criteria: Requests should be directed to the corresponding author and will be evaluated on the basis of scientific merit. Data will be shared after approval of a proposal and completion of a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 27 interventional studies with no phase under Intraoperative Complications, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 2, 2026
StartActual
Nov 15, 2024
Primary completionEst.
Apr 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854704
Lead sponsor
The Leningrad Regional Clinical Hospital
Collaborators
North-Western State Medical University named after I.I.Mechnikov
Responsible party
Kozlov Valentin Sergeevich (Anesthesiologist, Department of Anesthesiology and Intensive Care, The Leningrad Regional Clinical Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 15, 2024
Primary completion
Apr 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Valentin S Kozlov, MD
Contact
kozlov.vs@47lokb.ru
+7-931-250-79-30
Valentin S Kozlov, MD
principal investigator · The Leningrad Regional Clinical Hospital
Ionas S Simutis, MD, Dsc
principal investigator · North-Western State Medical University named after I.I.Mechnikov

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion